Kornimate/medical-research-clean huggingface dataset:
influence of a combined pharmacogenetic score on through plasma voriconazole concentrations in haematological patients

Conditions: Invasive Aspergillosis; Haematological Cancer Patients; Voriconazole

Summary: hypothesis: a pharmacogenetic score integrating both cyp3a genotypes could be influence initial trough voriconazole plasma concentrations and thus useful to adapt a priori voriconazole dosing in order to get adequate voriconazole exposure as possible after starting treatment. main objective: to determine predictive value of a combined pharmacogenetic score on onset of trough voriconazole plasma concentration inferior than lower therapeutic target.

voriconazole (vrc), the gold-standard treatment of invasive aspergillosis is characterized by variables and nonlinear pharmacokinetics, causing many under- or over-dosing. a link exist between trough plasma concentrations (cmin) of vrc and effectiveness but also its toxicity. thus the longitudinal therapeutic drug monitoring of vrc is now recommended with a therapeutic range between 1 and 5 mg/l. the pharmacokinetic variability of vrc is in part explained by its metabolism, mainly dependent on cytochrome p 450 (cyp), particularly cyp2c19, 3a4, 3a5; all these cyp exhibiting genetic polymorphisms. the authors, recently shown, and for the first time , in a retrospective study conducted in 29 patients allogeneic hematopoietic stem cell that initial vrc cmin adjusted the dose was not only influenced by the route of administration but also by a pharmacogenetics score whose determination is to assign each genotype cyp2c19 and cyp3a a score expressed in a arbitrary units. the combined pharmacogenetic score was strongly correlated with the original cmin (r= -0.748; p = 0.002) and was the only independent predictor of initial cmin (after adjusting the dose and the route of administration). in addition, none of the patients having a genetic score \ 2. the aim of this new study is to confirm the impact of the pharmacogenetic score on the initial vrc cmin over a larger prospective cohort of 60 adult patients with onco-hematological diseases.

Eligibility criteria:
inclusion criteria: * patients suffering from haematological cancer exclusion criteria: * less than 18-years old

Keywords: voriconazole pharmacogenetics pharmacokinetics therapeutic drug monitoring
evaluation of physical exercise to prevent functional deterioration during hospitalization (effapro)

Conditions: Cancer Patients; Hospitalized

Summary: this is a randomized study that will measure the possible benefit of supervised training during the hospitalization of patients with stage iv neoplasms in active treatment.

the trial is not going to be runned

Eligibility criteria:
inclusion criteria: * patients with stage iv neoplasms. * active treatment: chemotherapy, hormone therapy, immunotherapy or targeted therapies. * hospitalization at medical oncology departmentof the hospital puerta de hierro. * reason for hospitalization is expected to be solved in less than two weeks. exclusion criteria: * patients who do not wish to participate. * cognitive impairment. * hospitalization due to progression of oncological disease. * acute coronary syndrome or bone fracture in limbs during the previous three months.

Keywords: rehabilitation physical activity physical condition
vitamin d and mortality in heart failure

Conditions: Congestive Heart Failure

Summary: despite significant therapeutic improvements, congestive heart failure (chf) patients still have a poor prognosis. currently, 5-year survival rates are only 35-50%. there is an accumulating body of evidence from prospective cohort studies that low circulating 25-hydroxyvitamin d is an independent predictor of all-cause and cardiovascular mortality, respectively. vitamin d deficiency is prevalent among chf patients. we hypothesize that vitamin d may improve survival in chf patients. we therefore aimed to investigate whether vitamin d supplementation reduces mortality and increases event-free survival in end-stage chf patients.


Eligibility criteria:
inclusion criteria: * \> 18 years of age and \< 80 years of age * new york heart association functional class \> = ii exclusion criteria: * pregnancy and lactation * sarcoidosis * daily vitamin d intake \> 20 micrograms * serum 25-hydroxyvitamin d \> 30 ng/ml * hypercalcemia

Keywords: vitamin d, mortality, event-free survival, heart failure
peri-implant vitamin d and cathelicidin (ll-37) levels

Conditions: Peri-Implantitis and Peri-implant Mucositis

Summary: this research aims to explore the influence of vitamin d on the body's defense system by examining its impact on specific proteins involved in immune response and inflammation in the soft tissues surrounding dental implants. also aims to determine how vitamin d levels affect these proteins and their role in protecting peri-implant tissues from microbial infections and inflammation.

this cross-sectional clinical study examined 33 patients with 105 dental implants, classified as having either healthy peri-implant tissues or peri-implant diseases. participants had not received peri-implant treatment in the past six months or taken medications affecting peri-implant tissues in the last three months. eligible implants had been functional for at least 12 months with prosthetic superstructures that allowed sample collection. patients with uncontrolled systemic conditions, metabolic bone diseases, autoimmune disorders, or those who were pregnant or breastfeeding were excluded. clinical assessments were conducted at six peri-implant sites, measuring probing depth (pd), clinical attachment level (cal), modified plaque index (mpi), modified sulcus bleeding index (msbi), and keratinized mucosa width (kmw). bone loss was evaluated using radiographs. patients were categorized into three groups based on the 2017 classification of periodontal and peri-implant diseases: peri-implant health, peri-implant mucositis, and peri-implantitis (35 implants per group). peri-implant sulcus fluid (pisf) samples were collected for 25(oh)d and ll-37 analysis using enzyme-linked immunosorbent assay (elisa). statistical analysis included normality tests (kolmogorov-smirnov), descriptive statistics, one-way anova with tukey hsd, kruskal-wallis with dunn's test, chi-square tests, and spearman's correlation for non-normally distributed data.

Eligibility criteria:
inclusion criteria: * not received peri-implant treatment in the previous six months. * had not used vitamin d supplements, antibiotics, anti-inflammatory drugs, or any medications that could affect peri-implant tissues in the last three months. * patients with dental implants had been in function for at least 12 months, had been under functional loading for at least six months, and had prosthetic superstructures that allowed for unobstructed sample collection. exclusion criteria: * uncontrolled systemic conditions, disorders affecting peri-implant tissues, metabolic bone diseases, autoimmune disorders. * pregnancy or breastfeeding.

Keywords: peri-implant sulcus fluid peri-implant diseases ll-37 25(oh)d
neurobiological correlates of post traumatic stress disorder (ptsd) during rapid eye movement (rem) sleep

Conditions: Post-Traumatic Stress Disorder

Summary: the overarching aim of this exploratory/developmental research grant award (r21) is to explore the neurobiological correlates of ptsd during rem sleep by using state-of-the science positron emission tomography (pet) sleep imaging. this study will allow us to gain insight into the differences in sleep and waking brain mechanisms between veterans with ptsd and those without ptsd.


Eligibility criteria:
general inclusion criteria: * male oif/oef returnees between the ages of 18 and 45 years old * combat exposure scale score \> 17 * not taking medications known to affect sleep or wake function for at least 2 weeks (6 weeks for fluoxetine). * no history of trauma before age 18 specific inclusion criteria for subjects with ptsd: * meet diagnostic criteria for current ptsd according to the caps-1 * caps-1 score is less than 80 specific inclusion criteria for subjects without ptsd: * total caps-1 scores \< 17 * does not meet criteria for ptsd exclusion criteria: * trauma occurred less than 3 months prior to study entry * ces score \< 17 * taking medications known to affect sleep and / or brain glucose metabolism * current diagnosis of depression as determined by the scid or bdi score \> 13 * history of psychotic or bipolar disorder * current history (within 3 months) of substance or alcohol abuse as determined by the scid * positive alcohol blood test at screening or during the pet protocol * significant or unstable acute or chronic medical conditions * other current sleep disorders, such as insufficient sleep syndrome, delayed sleep phase syndrome, narcolepsy, restless legs syndrome, periodic leg movement disorder, obstructive sleep apnea, and current night shift work, suspected during the structured interview. individuals who are found to have a apnea-hypopnea index (ahi) \> 10 or an index of periodic leg movements with arousal \> 15 will be excluded. * presence of implanted devices such as cardiac pacemaker, aneurysm clip, ear implant, shrapnel, neurostimulators or other metal devices * fear of closed spaces * previous radiation. due to the risk of radiation exposure, we will exclude subjects who have had pet scans or other radiotracer exposure in the previous year. * history of open head injury.

Keywords: post traumatic stress disorder ptsd brain imaging pet neural sleep rem sleep
use of etco2 as a paco2 predictor under non invasive ventilation (niv) in cases of acute hypercapnic respiratory failure

Conditions: Hypercapnic Respiratory Failure

Summary: in patients treated by non invasive ventilation (niv) due to acute hypercapnic respiratory failure, the interest of using the end-tidal co2 measurement device "capnostream" to evaluate paco2 and paco2 variations over time will be evaluated. measurements will be done under normal expiration and under prolonged active and passive expiration maneuvers.


Eligibility criteria:
inclusion criteria: * icu patient equipped with arterial line * niv requirement * hypercapnia: paco2 \> 45mmhg exclusion criteria: * severe hemodynamic instability * severe psychiatric disorders * nasal lesions * denied consent

Keywords: acute respiratory failure hypercapnia non invasive ventilation end-tidal co2
maintain activity in arthritis: a feasibility study

Conditions: Arthritis

Summary: best practice guidelines across the world always recommend those living with arthritis to be physically active. research shows that being active can help people living with arthritis to do the things that they want to do for longer, reduce pain, improve quality of life and protect against getting other health conditions such as heart disease, lung disease and cancer. whilst various exercise programmes support people with arthritis to be active most individuals reduce their level of pa after completion of a prescribed programme. staying active in the longer-term is more difficult and there is often a decrease in activity over time. research has shown that exercise programmes helping people to become active, such as exercise classes, may not always have the right approach and focus during the programme to help people to stay active long-term. it is important to understand if people with arthritis can be supported to maintain their activity levels well in to the future. the investigators have already spoken to people living with arthritis, people involved in arthritis care and those involved in promoting physical activity. the research team brought their feedback and the scientific literature together and shaped a new intervention that suits the needs of people with arthritis and helps them to continue to be physically active. the investiagtors will now ask people living with arthritis to try out the new intervention. participants will receive up to five coaching sessions that aim to support people with arthritis to maintain their pa after exiting a structured exercise programme. sessions will be delivered within community venues in a group setting by a trained provider. sessions will last approximately between 60 and 90 minutes and will be delivered over a period of approximately 4-months. participants may receive a smartwatch with an inbuilt step counter such as fitbit and diary to record their daily steps or physical activity minutes. the diary will also be used to record physical activity maintenance goals, complete action plans and self-monitor progress to build new habits. participants can continue to use their own smartwatch if they have one. the research team are interested to know if the programme has any effect on the amount of activity people do over time as well as looking at factors which can help with the understanding of 'why' or 'why not' a pa intervention may have worked.


Eligibility criteria:
inclusion criteria: those who have exited from a supervised group-based exercise programme for arthritis. - exclusion criteria: those aged under 18 years -

Keywords: arthritis physical activity maintenance feasibility health coaching
etiology of recurrent varicose veins after stripping or ablation of superficial venous system

Conditions: Recurrent Varicose Vein of Lower Limb (Disorder)

Summary: number of patients and causes and patterns of recurrent varicose veins in the lower limbs in patients with history of varicose veins stripping or ablation of the superficial venous system.

recurrence of varicose veins following surgery is a common, complex and costly problem in vascular surgery. despite improvements in preoperative evaluation and methods of treatment, recurrence following varicose vein surgery is reported to occur in between 20 and 80% of cases. many theories have been put forward concerning the underlying mechanisms and causes. these include poor understanding of the venous anatomy and haemodynamics, inadequate preoperative assessment, inappropriate or incomplete surgery and development of new sites of venous reflux as a consequence of disease progression or neovascularisation. however, it is difficult to evaluate these suggestions since the studies from which they arise vary greatly in their definitions of recurrence, preoperative assessment, initial treatment, classification and method and duration of follow-up.

Eligibility criteria:
inclusion criteria: * 1) ages eligible for the study: 18-60. 2) sexes eligible for the study: all. 3) patients with previous intervention for varicose veins. 4) patients with primary or secondary varicosities. 5) patient's compliance to follow-up. exclusion criteria: 1) patients with no history of interventions for varicose veins. 2) patients treated with injection sclerotherapy alone. 3) pregnant women. 4) patients with arterial disease in the same limb (abi \<0.8). 5) patients with post-thrombotic syndrome -
preoperative estimation of disc herniation recurrence in patients with lumbar disc herniation

Conditions: Intervertebral Disc Herniation

Summary: this study will be conducted at research institute of traumatology and orthopedics (nrito) n.a. ya.l.tsivyan, novosibirsk, russia. the current study is prospective observational study to evaluate the efficacy of preoperative estimation of disc herniation recurrence among patients with lumbar disc herniation using predictive mathematical model at terms 3 years postoperatively . it is expected to enroll 350 patients aged 18-70 with lumbar disc herniation. risk estimation of disc herniation recurrence will be evaluated preoperatively, then patient will undergo conventional microdiscectomy. postoperative eximanation will include visits every 6-months during 3 years to evaluate clinical outcomes.


Eligibility criteria:
inclusion criteria: - age 18 to 60 years; single level lumbar disc herniation with neural compression confirmed on mri at one level of l4-l5 or l5-s1; 1. radicular leg pain with or without back pain; 2. symptoms persisting for at least four weeks prior to surgery; 3. given written informed consent; 4. able and agree to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements; 5. visual analogue scale score at least 40/100 at baseline. exclusion criteria: 1. more than one symptomatic level requiring multilevel surgical decompression 2. stenosis any etiology at the same level; 3. spondylolisthesis any etiology at the same level; 4. prior lumbar spinal surgery at any level; 5. other non-degenerative spinal conditions (e.g. infectious, traumatic, metabolic, inflammatory, neoplastic, structural or other pathology) that may have an impact on subject safety, wellbeing or the intent and conduct of the study 6. concurrent participation in another clinical study that may confound study results.
is a reporting system for gastritis or duodenitis (modified lanza scale) reproducible?

Conditions: Gastritis; Duodenitis

Summary: the modified lanza scale (lanza fl, 1984) has been widely utilized to grade the degree of gastritis and duodenitis. however, the inter-rater or intra-rater reproducibility of this scale has never been validated. as a quality improvement program, it is important to study the reproducibility of the scale between different operators and the operators himself. method: during upper endoscopic examinations, one investigator performed the procedure and the second investigator look at the endoscopic image. the degree of gastritis and duodenitis is graded. the results of the grading are blinded to the other investigator. the endoscopic video is stored for reassessment to determine the intra-rater reliability. the patient identifier is stored in serial number. the investigator will not retrieve the report of the first assessment during the second assessment.


Eligibility criteria:
all patients undergo upper endoscopy are included after written informed consent is obtained

Keywords: gastritis duodenitis inter-rater reliability intra-rater reliablity gastroscopy duodenoscopy
different administration routes of dexmedetomidine on postoperative delirium

Conditions: Dexmedetomidine; Postoperative Delirium; General Anesthesia

Summary: intravenous dexmedetomidine has been reported to decrease the occurrence of postoperative delirium (pod) in elderly patients. nevertheless, some previous studies have indicated that intratracheal dexmedetomidine and intranasal dexmedetomidine are also effective and convenient. the current study aimed to compare the effect of different administration routes of dexmedetomidine on pod in elderly patients.


Eligibility criteria:
inclusion criteria: older than 65 years; general anesthesia for more than two hours; exclusion criteria: -
open lung strategy during non-invasive respiratory support of very preterm infants in the delivery room

Conditions: Respiratory Distress Syndrome in Premature Infant; Non-invasive Ventilation; Lung Injury

Summary: the opening and aeration of the lung is critical for a successful transition from fetal to neonatal life. early nasal cpap in the delivery room in spontaneously breathing premature babies with a gestational age of 30 weeks or less is a standard treatment approach since it reduces the need for invasive mechanical ventilation and surfactant therapy. in respiratory distress syndrome (rds) management, providing optimal lung volumes in the very early period from the beginning of delivery room approaches probably augments the expected lung protective effect. although the benefits of cpap support are well known, standart cpap pressures recommended in the guidelines may not meet the needs of individual babies. maintaining lung patency in the delivery room is the main mechanism of action of cpap and the requirement may vary individually depending on lung physiology. in this multicenter randomized controlled study, we aimed to compare the effects of cpap therapy applied with a personalized open lung strategy (opencpap), and standard cpap therapy (standardcpap) on oxygenation, respiratory support need and surfactant treatment requirement in preterm babies with rds in the delivery room.


Eligibility criteria:
inclusion criteria: * infants born before 30 completed weeks of gestation and received early ncpap immediately after birth in delivery room exclusion criteria: * requirement of surfactant or endotracheal intubation or positive pressure ventilation before the completion of interventions * major congenital anomaly * transportation to another hospital

Keywords: nasal cpap delivery room open lung strategy peep respiratory distress syndrome individualised ventilation
human papillomavirus (hpv) registration study (gardasil)(v501-023)(completed)

Conditions: Papillomavirus Infections

Summary: this is an immunogenicity and safety study of gardasil (v501) in females 9 to 23 years of age in korea.


Eligibility criteria:
inclusion criteria: * girls ages 9 to 15 years (must not yet have had coitarche) * healthy females ages 16 to 23 years (individuals with a lifetime history of 0 to 3 male or female sexual partners) exclusion criteria: all subjects: * history of known prior vaccination with an hpv vaccine. women ages 16 to 23 only: * individuals with any prior history of genital warts or treatment for genital warts. * individuals with \> 3 lifetime male or female sexual partners.

Keywords: human papilloma virus
the effect of rifampin on the metabolism of istradefylline in healthy volunteers.

Conditions: Parkinson's Disease

Summary: the purpose of this study is to test whether rifampin affects blood levels of istradefylline in humans. rifampin could possibly decrease istradefylline levels.


Eligibility criteria:
inclusion criteria: * healthy non-smoking male and post-menopausal female subjects * body mass index: 18.0-35.0 kg/m2, inclusive * subjects must not be taking drugs that are moderate to potent inhibitors of cyp3a4 or cyp1a2. * subjects without clinically significant medical history in the judgment of the investigator * subjects without clinically significant laboratory or ecg abnormalities exclusion criteria: * females that are pregnant or lactating * administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study; * known history of treatment for drug or alcohol addiction within the previous 12 months; * subjects with an average alcohol intake of more than 2 units per day or 14 units per week up to 48 hours prior to the istradefylline dose on day 1. one unit of alcohol is ½ pint of beer (285 ml) or 1 glass of spirits (25 ml) or 1 glass of wine (125 ml); * donated or lost \> 500 ml of blood within 3 months prior to istradefylline dose on day 1 of period 1; * positive test results for human immunodeficiency virus (hiv) or hepatitis b surface antigen, or hepatitis c; * positive test results for drugs of abuse at screening; * unable, or unwilling to tolerate multiple venipunctures; * difficulty fasting or eating the standard meals that will be provided; * use of tobacco or nicotine-containing products within 90 days of the study start to the follow-up visit

Keywords: pd
a study with ly293111, gemcitabine and placebo in patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to determine the effectiveness and side effects of ly293111 given in combination with gemcitabine in patients with pancreatic cancer.


Eligibility criteria:
inclusion criteria: * adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent * tumor that can be measured by x-ray or scan * adequate organ function exclusion criteria: * inability to swallow capsules * documented brain metastases * prior chemotherapy or biological therapy for this disease